Literature DB >> 21774879

Improving surgical access: the Vancouver experience.

Daniel H Williams1, Carolyn Iker, Laurie Leith, Bassam A Masri.   

Abstract

The University of British Columbia Hospital program was designed to augment existing provincial capacity for hip and knee replacement. The patient-surgeon relationship was maintained throughout the entire care pathway and "ring-fenced" capacity (i.e., designated hospital ward bed and operating room capacity that is geographically remote from the emergency intake of patients) minimized the risk of cancellations. Analysis of the results revealed a mean patient satisfaction score of 4.7 out of 5, a complication rate of 4.4%, a mean operating room time of 1 hour and 45 minutes and a mean postoperative length of stay in hospital of 3.4 days. More than 1600 joint replacements -- an additional 16% provincial capacity -- were performed within budget during each of the first 2 years of operation. A high standard of care was maintained, with high rates of patient satisfaction and a low complication rate.

Entities:  

Mesh:

Year:  2011        PMID: 21774879      PMCID: PMC3191903          DOI: 10.1503/cjs.020110

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  3 in total

1.  Quality of elective surgery in treatment centres.

Authors:  S R Cannon
Journal:  J Bone Joint Surg Br       Date:  2009-02

2.  Further doubts over the performance of treatment centres in providing elective orthopaedic surgery.

Authors:  S Oussedik; F Haddad
Journal:  J Bone Joint Surg Br       Date:  2009-09

3.  Can the English NHS meet the 18-week waiting list target?

Authors:  Richard Lewis; John Appleby
Journal:  J R Soc Med       Date:  2006-01       Impact factor: 18.000

  3 in total
  1 in total

1.  A patient-centred approach toward surgical wait times for colon cancer: a population-based analysis.

Authors:  Amy Gillis; Matthew Dixon; Andrew Smith; Calvin Law; Natalie G Coburn
Journal:  Can J Surg       Date:  2014-04       Impact factor: 2.089

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.